Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.
Rosa DD, Magliano CADS, Simon SD, Amorim G, Reinert T, Landeiro L, Gagliato DM, Exman P, Argolo D, Guilgen G, Mano M, Testa L, Liedke P, Barroso R, Sasse M, Buehler AM.
Rosa DD, et al. Among authors: barroso r.
Ther Adv Med Oncol. 2022 Jun 20;14:17588359221100865. doi: 10.1177/17588359221100865. eCollection 2022.
Ther Adv Med Oncol. 2022.
PMID: 36339925
Free PMC article.